Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Public ClinicalTrials.gov record NCT01908426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Study identification
- NCT ID
- NCT01908426
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 707 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2013
- Primary completion
- Oct 15, 2017
- Completion
- Jan 11, 2021
- Last update posted
- May 5, 2021
2013 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Corona | California | 92879 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Atlanta | Georgia | 30318 | — |
| Not listed | Honolulu | Hawaii | 96815 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Burlington | Massachusetts | 01805 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Kansas City | Missouri | 64128 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89109 | — |
| Not listed | East Orange | New Jersey | 07018 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Valhalla | New York | 10595 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | Seattle | Washington | 98104 | — |
| Not listed | Seattle | Washington | 98109 | — |
| Not listed | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01908426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2021 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01908426 live on ClinicalTrials.gov.